CI: Monitoring Criteria: Promotility Agents (2006)
What is the relationship between the use of promotility agents (e.g., metoclopramide) and enteral feeding tolerance in critically ill patients?
Use of promotility agents (e.g., metoclopramide) or small bowel EN is associated with reduced GRV in critically ill patients.
- Grade I means there is Good/Strong evidence supporting the statement;
- Grade II is Fair;
- Grade III is Limited/Weak;
- Grade IV is Expert Opinion Only;
- Grade V is Not Assignable.
Evidence Summary: What is the relationship between the use of promotility agents (e.g., metoclopramide) and enteral feeding tolerance in critically ill patients?
- Quality Rating Summary
For a summary of the Quality Rating results, click here.
- Boivin MA, Levy H. Gastric feeding with erythromycin is equivalent to transpyloric feeding in the critically ill. Crit Care Med 2001; 39 (10): 1,916-1,919.
- Booth CM, Heyland DK, Paterson WG. Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence. Crit Care Med 2002; 30:1429-1435.
- Esparza J, Boivin MA, Hartshorne MF, Levy H. Equal aspiration rates in gastrically and transpylorically fed critically ill patients. Intens Care Med 2001; 27: 660-664.
- Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN. 2003; 27: 355-373.
- Pinilla JC, Samphire J, Arnold C, et al. Comparison of gastrointestinal tolerance to two enteral feeding protocols in critically ill patients: A prospective, randomized controlled trial. JPEN 2001; 25:81-86.
- Yavagal DR, Karnad DR, Oak JL. Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: A randomized controlled trial. Crit Med 2000;28:1401-1411.
Search Plan and Results: CI: Monitoring Criteria in Critical Illness 2003